GlassScriptPhysician profile
James C Rholl
NPI 1053360982
$4,294.34
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $337 · 2021: $723 · 2022: $1,488 · 2023: $931 · 2024: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,233.47 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $406.17 | 2019-2024 | Xifaxan, Plenvu |
| Ironwood Pharmaceuticals, INC | $335.89 | 2019-2023 | Linzess |
| Janssen Biotech, INC. | $326.25 | 2019-2024 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $312.26 | 2019-2024 | Gattex, Entyvio |
| Gilead Sciences, INC. | $300.48 | 2021-2024 | |
| Janssen Scientific Affairs, LLC | $150.00 | 2022 | |
| Nestle Healthcare Nutrition INC. | $141.77 | 2021-2022 | |
| Celgene Corporation | $141.50 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $126.80 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $125.00 | 2019 | |
| Merck Sharp & Dohme LLC | $100.88 | 2019-2023 | Dificid |
| Genzyme Corporation | $96.21 | 2022-2023 | |
| Pfizer INC. | $81.01 | 2019-2023 | |
| Organon LLC | $62.69 | 2023 | Hadlima, Renflexis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $56.35 | 2022-2024 | Dupixent |
| Romark Laboratories, Lc | $51.39 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $45.99 | 2022-2023 | Cimzia |
| Intra-Sana Laboratories | $44.76 | 2021-2022 | |
| Lilly USA, LLC | $32.96 | 2023-2024 | Omvoh |
| Qol Medical, LLC | $29.38 | 2023 | Sucraid |
| Axonics, INC. | $25.20 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $23.19 | 2023 | Idacio |
| Braintree Laboratories, INC. | $20.32 | 2023 | Sutab |
| Ucb, INC. | $13.40 | 2019 | |
| Shionogi INC | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rholl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.